Prateek J. Khatri, MD; John G. Webb, MD; Josep Rodés-Cabau, MD; Stephen E. Fremes, MD; Marc Ruel, MD; Kelly Lau, BSc; Helen Guo, MSc; Harindra C. Wijeysundera, MD, PhD; Dennis T. Ko, MD, MSc
Grant Support: Dr. Ko is supported by a Canadian Institutes of Health Research New Investigator Award. Study analyses were funded in part by operating grants from the Heart and Stroke Foundation of Canada.
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-0299.
Requests for Single Reprints: Dennis T. Ko, MD, MSc, Institute for Clinical Evaluative Sciences, G1-06, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada; e-mail, email@example.com.
Current Author Addresses: Drs. Khatri and Ko, Ms. Lau, and Ms. Guo: Institute for Clinical Evaluative Sciences, G1-06, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
Dr. Webb: University of British Columbia, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada.
Dr. Rodés-Cabau: Quebec Heart and Lung Institute, 2725 chemin Ste-Foy, Québec City, Québec G1V 4G5, Canada.
Drs. Fremes and Wijeysundera: Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
Dr. Ruel: University of Ottawa Heart Institute 40 Ruskin Street, Suite 3403 Ottawa, Ontario K1Y 4W7, Canada.
Author Contributions: Conception and design: P.J. Khatri, M. Ruel, H. Guo, D.T. Ko.
Analysis and interpretation of the data: P.J. Khatri, J.G. Webb, J. Rodés-Cabau, S.E. Fremes, M. Ruel, H. Guo, H.C. Wijeysundera, D.T. Ko.
Drafting of the article: P.J. Khatri, J.G. Webb, D.T. Ko.
Critical revision of the article for important intellectual content: P.J. Khatri, J.G. Webb, J. Rodés-Cabau, S.E. Fremes, M. Ruel, H.C. Wijeysundera, D.T. Ko.
Final approval of the article: P.J. Khatri, J.G. Webb, J. Rodés-Cabau, S.E. Fremes, M. Ruel, H.C. Wijeysundera, D.T. Ko.
Statistical expertise: M. Ruel, H. Guo.
Obtaining of funding: D.T. Ko.
Administrative, technical, or logistic support: K. Lau.
Collection and assembly of data: P.J. Khatri, K. Lau, D.T. Ko.
Khatri PJ, Webb JG, Rodés-Cabau J, Fremes SE, Ruel M, Lau K, et al. Adverse Effects Associated With Transcatheter Aortic Valve Implantation: A Meta-analysis of Contemporary Studies. Ann Intern Med. 2013;158:35-46. doi: 10.7326/0003-4819-158-1-201301010-00007
Download citation file:
Published: Ann Intern Med. 2013;158(1):35-46.
Transcatheter aortic valve implantation (TAVI) has emerged as an important treatment for patients with severe symptomatic aortic stenosis who are at high operative risk, but accurate estimates of serious adverse effects in contemporary practice are not available.
To quantify the adverse effects associated with TAVI, and to evaluate whether the type of transcatheter valve and the route of valve implantation are associated with differences in adverse outcomes.
PubMed to 5 May 2012.
All studies that included at least 100 patients who had TAVI and reported at least 1 outcome of interest.
Two reviewers abstracted the data independently. A random-effects model was used to combine data on adverse outcomes and conduct stratified analyses.
A total of 49 studies enrolling 16 063 patients met the inclusion criteria. Overall 30-day and 1-year survival after TAVI were 91.9% (95% CI, 91.1% to 92.8%) and 79.2% (CI, 76.9% to 81.4%), respectively. Heart block requiring permanent pacemaker implantation was the most common adverse outcome (13.1%) and was 5 times more common with the CoreValve (Medtronic, Minneapolis, Minnesota) than the Sapien valve (Edwards Lifesciences, Irving, California) implanted using the transarterial route (25.2% vs. 5.0%, respectively). The overall rate of vascular complications was 10.4% and was highest with transarterial implantation of the Sapien valve (22.3%). Acute renal failure requiring renal replacement therapy was the third most common complication, occurring in 4.9% of patients.
Rates of major vascular complications may be overestimated owing to rapidly evolving TAVI technology.
The most common adverse effects associated with TAVI are heart block, vascular complications, and renal failure. The type of transcatheter valve and the route of implantation are associated with observed variations in the risks for some adverse effects.
Heart and Stroke Foundation of Canada.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Valvular Heart Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only